nach oben

Current Gastroenterology Reports

Erschienen in:

01.05.2018 | Pediatric Gastroenterology (S Orenstein, Section Editor)

Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease

verfasst von: Nicholas Carman, David R. Mack, Eric I. Benchimol

Erschienen in: Current Gastroenterology Reports | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Therapeutic drug monitoring (TDM) has emerged as a useful tool to optimize the use of drug therapies in adults with inflammatory bowel disease (IBD), including both Crohn’s disease (CD) and ulcerative colitis (UC), especially during the use of biological therapies, for which the pharmacokinetics and pharmacodynamics are highly variable among patients. Fewer data exist in children. This review examines the current literature on TDM in pediatric IBD.

Recent findings

Drug clearance is affected by a number of patient and disease factors. For thiopurines, adjusting dosing by monitoring 6-thioguanine (6TGN) and 6-methylmercaptopurine ((6MMP) levels is demonstrated to maximize response and minimize toxicity, while monitoring metabolite levels when treating with anti-tumor necrosis factor (anti-TNF) remain controversial. While in adults the use of TDM in the setting of loss of response to anti-TNF therapy is established, in children, only a small number of studies exist, but these too have encouraging results. There are however, conflicting data regarding the optimal timing of TDM, comparing “reactive” monitoring and “proactive” monitoring. No such data exist in pediatrics. TDM is cost-effective, and dose reduction may represent a safety benefit. There are limited adult data for use of TDM for the newer biologics, vedolizumab and ustekinumab, but early results suggest similarly promising utility.

Summary

The use of TDM in pediatric IBD is increasing in clinical practice, with similar efficacy to adults demonstrated in children with loss of response to anti-TNF therapy. More prospective studies are needed in children to examine proactive monitoring and utility of TDM with newer biologics.

Benchimol EI, Manuel DG, Guttmann A, Nguyen GC, Mojaverian N, Quach P, et al. Changing age demographics of inflammatory bowel disease in Ontario, Canada: a population-based cohort study of epidemiology trends. Inflamm Bowel Dis. 2014;20(10):1761–9. https://doi.org/10.1097/mib.0000000000000103.PubMedCrossRef

Benchimol EI, Mack DR, Nguyen GC, Snapper SB, Li W, Mojaverian N, et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology. 2014;147(4):803–13.e7; quiz e14–5. https://doi.org/10.1053/j.gastro.2014.06.023.PubMedCrossRef

Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Singh H, Otley AR, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol. 2017;112(7):1120–34. https://doi.org/10.1038/ajg.2017.97.PubMedPubMedCentralCrossRef

Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035–58.e3. https://doi.org/10.1053/j.gastro.2015.03.001.PubMedCrossRef

Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–34. https://doi.org/10.1053/j.gastro.2017.07.032.PubMedCrossRef

Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47(3):212–21. https://doi.org/10.1097/MCG.0b013e3182732ff5.PubMedCrossRef

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. https://doi.org/10.1056/NEJMoa0904492.PubMedCrossRef

Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65. https://doi.org/10.1053/j.gastro.2006.11.041.PubMedCrossRef

Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–59, quiz 60. https://doi.org/10.1038/ajg.2011.73.PubMedCrossRef

10.

Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391–9.e1. https://doi.org/10.1016/j.cgh.2011.11.026.PubMedCrossRef

11.

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863–73; quiz 1165-6. https://doi.org/10.1053/j.gastro.2006.12.003.PubMedCrossRef

12.

•• Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143(2):365–74.e2. https://doi.org/10.1053/j.gastro.2012.04.046. Relationship between adalimumab levels and ADAs in Pediatric CD. PubMedCrossRef

13.

Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121–6. https://doi.org/10.1097/mib.0000000000000865.PubMedCrossRef

14.

Conrad MA, Stein RE, Maxwell EC, Albenberg L, Baldassano RN, Dawany N, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425–31. https://doi.org/10.1097/mib.0000000000000918.PubMedCrossRef

15.

Bishop C, Simon H, Suskind D, Lee D, Wahbeh G. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2016;63(3):348–51. https://doi.org/10.1097/mpg.0000000000001146.PubMedCrossRef

16.

Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: a large single centre experience. J Crohns Colitis. 2012;6(2):143–53. https://doi.org/10.1016/j.crohns.2011.07.011.PubMedCrossRef

17.

Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135. https://doi.org/10.1038/ctg.2015.63.PubMedPubMedCentralCrossRef

18.

Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–95. https://doi.org/10.1111/j.1365-2036.2011.04612.x.PubMedCrossRef

19.

D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106(2):199–212; quiz 3. https://doi.org/10.1038/ajg.2010.392.PubMedCrossRef

20.

Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;9:101–11. https://doi.org/10.2147/cpaa.S138414.PubMedPubMedCentralCrossRef

21.

Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn’s disease who lose clinical response. Aliment Pharmacol Ther. 2018;47(3):346–55. https://doi.org/10.1111/apt.14452.PubMedCrossRef

22.

Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104(3):760–7. https://doi.org/10.1038/ajg.2008.88.PubMedCrossRef

23.

Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8(10):1179–207. https://doi.org/10.1016/j.crohns.2014.04.005.PubMedCrossRef

24.

Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340–61. https://doi.org/10.1097/MPG.0b013e3182662233.PubMedCrossRef

25.

Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118(6):1025–30.PubMedCrossRef

26.

Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2(9):731–43.PubMedCrossRef

27.

Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296–307.e5. https://doi.org/10.1053/j.gastro.2014.08.035.PubMedCrossRef

28.

Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(4):543–9. https://doi.org/10.1016/j.cgh.2015.11.014.PubMedCrossRef

29.

Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721–7. https://doi.org/10.1136/gutjnl-2012-304094.PubMedPubMedCentralCrossRef

30.

Papamichael K, Cheifetz AS. Higher Adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease. J Crohns Colitis. 2016;10(5):507–9. https://doi.org/10.1093/ecco-jcc/jjw041.PubMedPubMedCentralCrossRef

31.

Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, et al. Optimizing Anti-TNF-alpha therapy: serum levels of Infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14(4):550–7.e2. https://doi.org/10.1016/j.cgh.2015.10.025.PubMedCrossRef

32.

Baert F, Noman M, Vermeire S, Van Assche G, DH G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8. https://doi.org/10.1056/NEJMoa020888.PubMedCrossRef

33.

Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003. https://doi.org/10.1097/mib.0000000000000156.PubMedPubMedCentralCrossRef

34.

Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective, randomized trial. J Crohns Colitis. 2016;10(11):1259–66. https://doi.org/10.1093/ecco-jcc/jjw152.PubMedCrossRef

35.

Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118(4):705–13.PubMedCrossRef

36.

Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122(4):904–15.PubMedCrossRef

37.

Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651–62.PubMedPubMedCentral

38.

Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130(4):1047–53. https://doi.org/10.1053/j.gastro.2006.01.046.PubMedCrossRef

39.

•• Lee MN, Kang B, Choi SY, Kim MJ, Woo SY, Kim JW, et al. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis. 2015;21(5):1054–62. https://doi.org/10.1097/mib.0000000000000347. Relationship between 6TGN levels and clinical outcome for azathioprine in Pediatric IBD. PubMedCrossRef

40.

•• Kopylov U, Amre D, Theoret Y, Deslandres C, Seidman EG. Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2014;59(4):511–5. https://doi.org/10.1097/mpg.0000000000000455. Relationship between 6TGN levels and clinical outcome for azathioprine in Pediatric CD. PubMedCrossRef

41.

Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3. https://doi.org/10.1053/j.gastro.2013.10.052.PubMedCrossRef

42.

Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344–54.e5; quiz e14–5. https://doi.org/10.1053/j.gastro.2014.10.011.PubMedCrossRef

43.

Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13(6):1118–24.e3. https://doi.org/10.1016/j.cgh.2014.12.026.PubMedCrossRef

44.

Kariyawasam VC, Ward MG, Blaker PA, Patel KV, Goel R, Sanderson JD, et al. Thiopurines dosed to a therapeutic 6-Thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing Crohn’s disease. Inflamm Bowel Dis. 2017;23(9):1555–65. https://doi.org/10.1097/mib.0000000000001183.PubMedCrossRef

45.

Nuti F, Civitelli F, Bloise S, Oliva S, Aloi M, Latorre G, et al. Prospective evaluation of the achievement of mucosal healing with anti-TNF-alpha therapy in a paediatric Crohn’s disease cohort. J Crohns Colitis. 2016;10(1):5–12. https://doi.org/10.1093/ecco-jcc/jjv126.PubMedCrossRef

46.

Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291–302. https://doi.org/10.1111/apt.14030.PubMedCrossRefPubMedCentral

47.

Walters TD, Faubion WA, Griffiths AM, Baldassano RN, Escher J, Ruemmele FM, et al. Growth improvement with adalimumab treatment in children with moderately to severely active Crohn’s disease. Inflamm Bowel Dis. 2017;23(6):967–75. https://doi.org/10.1097/mib.0000000000001075.PubMedCrossRef

48.

Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23(3):453–60. https://doi.org/10.1097/mib.0000000000001021.PubMedPubMedCentralCrossRef

49.

Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146(2):383–91. https://doi.org/10.1053/j.gastro.2013.10.027.PubMedCrossRef

50.

Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21(1):182–97. https://doi.org/10.1097/mib.0000000000000202.PubMedCrossRef

51.

Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16(10):1277–90. https://doi.org/10.1080/14712598.2016.1203897.PubMedCrossRef

52.

Chaparro M, Panes J, Garcia V, Merino O, Nos P, Domenech E, et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis. 2012;18(4):685–90. https://doi.org/10.1002/ibd.21758.PubMedCrossRef

53.

Chaparro M, Panes J, Garcia V, Manosa M, Esteve M, Merino O, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol. 2011;45(2):113–8. https://doi.org/10.1097/MCG.0b013e3181ebaef9.PubMedCrossRef

54.

Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–46. https://doi.org/10.1038/clpt.2011.328.PubMedCrossRef

55.

Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48(5):297–308.PubMedCrossRef

56.

Papamichael K, Cheifetz AS. Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy. Am J Gastroenterol. 2017;112(5):673–6. https://doi.org/10.1038/ajg.2017.21.PubMedCrossRef

57.

Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2017:gutjnl-2016-313071. https://doi.org/10.1136/gutjnl-2016-313071.

58.

•• Adedokun OJ, Xu Z, Padgett L, Blank M, Johanns J, Griffiths A, et al. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. Inflamm Bowel Dis. 2013;19(13):2753–62. https://doi.org/10.1097/01.MIB.0000435438.84365.f7. Relationship between IFX trough levels and clinical outcome in Pediatric UC. PubMedCrossRef

59.

Bendtzen K. Immunogenicity of anti-TNF-alpha biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol. 2015;6:109. https://doi.org/10.3389/fimmu.2015.00109.PubMedPubMedCentralCrossRef

60.

Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382(1–2):177–88. https://doi.org/10.1016/j.jim.2012.06.002.PubMedCrossRef

61.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109(7):1055–64. https://doi.org/10.1038/ajg.2014.106.PubMedCrossRef

62.

Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut. 1995;36(6):897–901.PubMedPubMedCentralCrossRef

63.

Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650–60. https://doi.org/10.1097/mib.0000000000001043.PubMedCrossRef

64.

Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–5.e2. https://doi.org/10.1053/j.gastro.2015.04.016.PubMedCrossRef

65.

Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(2):330–5.e1. https://doi.org/10.1016/j.cgh.2014.07.041.PubMedCrossRef

66.

• Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, et al. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD. J Pediatr Gastroenterol Nutr. 2014;58(2):213–9. https://doi.org/10.1097/MPG.0b013e3182a98df2. Relationship between infliximab trough levels and infliximab failure in Pediatric IBD. PubMedCrossRef

67.

Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–81. https://doi.org/10.1080/00365520802699278.PubMedCrossRef

68.

Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108(1):40–7; quiz 8. https://doi.org/10.1038/ajg.2012.363.PubMedCrossRef

69.

Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015;64(10):1539–45. https://doi.org/10.1136/gutjnl-2014-307883.PubMedCrossRef

70.

•• Choi SY, Kang B, Lee JH, Choe YH. Clinical use of measuring trough levels and antibodies against infliximab in patients with pediatric inflammatory bowel disease. Gut Liver. 2017;11(1):55–61. https://doi.org/10.5009/gnl16041. Relationship between infliximab trough levels, ADAs and clinical outcome in Pediatric IBD. PubMedCrossRef

71.

•• Merras-Salmio L, Kolho KL. Clinical use of infliximab trough levels and antibodies to infliximab in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64(2, 272):–8. https://doi.org/10.1097/mpg.0000000000001258. Relationship between infliximab trough levels, ADAs and clinical outcome in Pediatric IBD.

72.

• Deora V, Kozak J, El-Kalla M, Huynh HQ, El-Matary W. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease. Acta Paediatr. 2017;106(11):1863–7. https://doi.org/10.1111/apa.14008. Use of TDM to guide clinical decision making for infliximab in Pediatric IBD. PubMedCrossRef

73.

• Frymoyer A, Hoekman DR, Piester TL, de Meij TG, Hummel TZ, Benninga MA, et al. Application of population pharmacokinetic modeling for individualized infliximab dosing strategies in Crohn Disease. J Pediatr Gastroenterol Nutr. 2017;65(6):639–45. https://doi.org/10.1097/mpg.0000000000001620. Use of population PK to predict infliximab trough levels in Pediatric CD. PubMedCrossRef

74.

• Hamalainen A, Sipponen T, Kolho KL. Serum infliximab concentrations in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2013;48(1):35–41. https://doi.org/10.3109/00365521.2012.741619. Relationship between maintenance infliximab trough levels and clinical outcome in Pediatric IBD. PubMedCrossRef

75.

•• Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Lowenberg M, Benninga MA, et al. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2015;50(9):1110–7. https://doi.org/10.3109/00365521.2015.1027264. Relationship between maintenance infliximab trough levels and clinical outcome in Pediatric IBD. PubMedCrossRef

76.

• Hofmekler T, Bertha M, McCracken C, Martineau B, McKinnon E, Schoen BT, et al. Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64(4):580–5. https://doi.org/10.1097/mpg.0000000000001302. Relationship between dose and interval for infliximab trough levels. PubMedCrossRef

77.

• Minar P, Saeed SA, Afreen M, Kim MO, Denson LA. Practical use of infliximab concentration monitoring in pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2016;62(5):715–22. https://doi.org/10.1097/mpg.0000000000001029. Use of TDM to guide clinical decision making for infliximab in Pediatric CD. PubMedPubMedCentralCrossRef

78.

•• Rolandsdotter H, Marits P, Sundin U, Wikstrom AC, Fagerberg UL, Finkel Y, et al. Serum-infliximab trough levels in 45 children with inflammatory bowel disease on maintenance treatment. Int J Mol Sci. 2017;18(3) https://doi.org/10.3390/ijms18030575. Relationship between maintenance infliximab trough levels and clinical outcome in Pediatric IBD.

79.

•• Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(10):1708–13. https://doi.org/10.1097/mib.0000000000000137. Relationship between post induction infliximab trough levels and clinical outcome in Pediatric IBD. PubMedCrossRef

80.

• Stein R, Lee D, Leonard MB, Thayu M, Denson LA, Chuang E, et al. Serum infliximab, antidrug antibodies, and tumor necrosis factor predict sustained response in pediatric Crohn’s disease. Inflamm Bowel Dis. 2016;22(6):1370–7. https://doi.org/10.1097/mib.0000000000000769. Relationship between post induction infliximab trough levels and infliximab continuation in Pediatric CD. PubMedCrossRef

81.

• Zitomersky NL, Atkinson BJ, Fournier K, Mitchell PD, Stern JB, Butler MC, et al. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm Bowel Dis. 2015;21(2):307–14. https://doi.org/10.1097/mib.0000000000000284. Relationship between infliximab ADAs and clinical outcomes in Pediatric IBD. PubMedPubMedCentralCrossRef

82.

•• Dubinsky MC, Rosh J, Faubion WA Jr, Kierkus J, Ruemmele F, Hyams JS, et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patientS with Crohn’s disease. Inflamm Bowel Dis. 2016;22(4):886–93. https://doi.org/10.1097/mib.0000000000000715. Relationship between adalimumab trough levels and clinical outcome in Pediatric CD. PubMedPubMedCentralCrossRef

83.

Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21(4):783–92. https://doi.org/10.1097/mib.0000000000000327.PubMedCrossRef

84.

Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71. https://doi.org/10.1038/ajg.2013.12.PubMedCrossRef

85.

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522–30.e2. https://doi.org/10.1016/j.cgh.2014.07.029.PubMedCrossRef

86.

Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444–7. https://doi.org/10.1016/j.cgh.2012.10.020.PubMedCrossRef

87.

Ungar B, Kopylov U, Engel T, Yavzori M, Fudim E, Picard O, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45(2):276–82. https://doi.org/10.1111/apt.13862.PubMedCrossRef

88.

Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–8.e1. https://doi.org/10.1053/j.gastro.2013.11.024.PubMedCrossRef

89.

Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(10):1748–56. https://doi.org/10.1016/j.cgh.2015.04.010.PubMedCrossRef

90.

Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–31. https://doi.org/10.1136/gut.2006.099978.PubMedPubMedCentralCrossRef

91.

Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2(7):542–53.PubMedCrossRef

92.

Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease, Clin Gastroenterol Hepatol. 2015;13(3):514–21.e4. https://doi.org/10.1016/j.cgh.2014.07.027.

93.

O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(1):1–6. https://doi.org/10.1097/01.MIB.0000436951.80898.6d.PubMedCrossRef

94.

Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–54. https://doi.org/10.1016/j.cgh.2006.06.025.PubMedCrossRef

95.

Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohns Colitis. 2013;7(9):736–43. https://doi.org/10.1016/j.crohns.2012.10.019.PubMedCrossRef

96.

Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49–54. https://doi.org/10.1136/gut.2009.183095.PubMedCrossRef

97.

Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18(2):201–11. https://doi.org/10.1002/ibd.21697.PubMedCrossRef

98.

Barnes EL, Allegretti JR. Are anti-tumor necrosis factor trough levels predictive of mucosal healing in patients with inflammatory bowel disease?: a systematic review and meta-analysis. J Clin Gastroenterol. 2016;50(9):733–41. https://doi.org/10.1097/mcg.0000000000000441.PubMedCrossRef

99.

Joosse ME, Samsom JN, van der Woude CJ, Escher JC, van Gelder T. The role of therapeutic drug monitoring of anti-tumor necrosis factor alpha agents in children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(9):2214–21. https://doi.org/10.1097/mib.0000000000000420.PubMedCrossRef

100.

Liefferinckx C, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, et al. Infliximab trough levels at induction to predict treatment failure during maintenance. Inflamm Bowel Dis. 2017;23(8):1371–81. https://doi.org/10.1097/mib.0000000000001120.PubMedCrossRef

101.

Bodini G, Giannini EG, Savarino V, Del Nero L, Lo Pumo S, Brunacci M, et al. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. Dig Liver Dis. 2017; https://doi.org/10.1016/j.dld.2017.11.008.

102.

Davidov Y, Ungar B, Bar-Yoseph H, Carter D, Haj-Natour O, Yavzori M, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis. 2017;11(5):549–55. https://doi.org/10.1093/ecco-jcc/jjw182. PubMedCrossRef

103.

Crowley ECN, Mack DR, El-Matery W, Frost K, Arpino V, Benchimol EI, et al. Griffiths AM. Therapeutic drug monitoring during infiximab induction in paedaitric IBD: A multi-centre prospective cohort study. PIBD; 2017. p. 2017.

104.

Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9.e3. https://doi.org/10.1053/j.gastro.2015.02.031.PubMedCrossRef

105.

D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, or corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018; https://doi.org/10.1053/j.gastro.2018.01.004.

106.

Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580–8.e3. https://doi.org/10.1016/j.cgh.2017.03.031.PubMedCrossRefPubMedCentral

107.

Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933–40. https://doi.org/10.1111/apt.13970.PubMedCrossRef

108.

Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–27. https://doi.org/10.1136/gutjnl-2013-305279.PubMedCrossRef

109.

Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11(6):654–66. https://doi.org/10.1016/j.cgh.2012.12.035.PubMedCrossRef

110.

Roblin X, Attar A, Lamure M, Savarieau B, Brunel P, Duru G, et al. Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn’s disease patients who lose response to infliximab. J Mark Access Health Policy. 2015;3 https://doi.org/10.3402/jmahp.v3.29229.

111.

Andrade P, Lopes S, Gaspar R, Nunes A, Magina S, Macedo G. Anti-tumor necrosis factor-alpha-induced dermatological complications in a large cohort of inflammatory bowel disease patients. Dig Dis Sci. 2018;63:746–54. https://doi.org/10.1007/s10620-018-4921-y.PubMedCrossRef

112.

Freling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110(8):1186–96. https://doi.org/10.1038/ajg.2015.205.PubMedCrossRef

113.

Rivera-Nieves J. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments. Curr Opin Gastroenterol. 2015;31(6):441–8. https://doi.org/10.1097/mog.0000000000000218.PubMedPubMedCentralCrossRef

114.

Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–21. https://doi.org/10.1111/apt.14167.PubMedCrossRef

115.

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. https://doi.org/10.1056/NEJMoa1215734.PubMedCrossRef

116.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. https://doi.org/10.1056/NEJMoa1215739.PubMedCrossRef

117.

Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, et al. Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn’s disease. J Crohns Colitis. 2017;11(8):921–9. https://doi.org/10.1093/ecco-jcc/jjx021.PubMedCrossRef

118.

Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, et al. Association of vedolizumab level, anti-drug antibodies, and alpha4beta7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017; https://doi.org/10.1016/j.cgh.2017.11.050.

119.

Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin Gastroenterol Hepatol. 2017;15(11):1750–7.e3. https://doi.org/10.1016/j.cgh.2016.11.023.PubMedCrossRef

120.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60. https://doi.org/10.1056/NEJMoa1602773.PubMedCrossRef

121.

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84. https://doi.org/10.1016/s0140-6736(08)60726-6.PubMedCrossRef

122.

Adedokun OJXZ, Gasink C, et al. Sa1934 pharmacokinetics and exposure response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn’s disease with ustekinumab: results from the UNITI-1, UNITI-2 aand IM-UNITI studies. Gastroenterology. 2016;150(4):S408.

123.

Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15(9):1427–34.e2. https://doi.org/10.1016/j.cgh.2017.03.032.PubMedCrossRef

Titel: Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
verfasst von: Nicholas Carman
David R. Mack
Eric I. Benchimol
Publikationsdatum: 01.05.2018
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 5/2018
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-018-0623-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Health Maintenance in Inflammatory Bowel Disease

Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate

Applications of Colon Capsule Endoscopy

Update on the Therapeutic Management of Hepatic Encephalopathy

Therapy for Crohn’s Disease: a Review of Recent Developments